4YJU

THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000249


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.67 Å
  • R-Value Free: 0.201 
  • R-Value Work: 0.167 
  • R-Value Observed: 0.168 

wwPDB Validation   3D Report Full Report



Literature

Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor.

Liddle, J.Atkinson, F.L.Barker, M.D.Carter, P.S.Curtis, N.R.Davis, R.P.Douault, C.Dickson, M.C.Elwes, D.Garton, N.S.Gray, M.Hayhow, T.G.Hobbs, C.I.Jones, E.Leach, S.Leavens, K.Lewis, H.D.McCleary, S.Neu, M.Patel, V.K.Preston, A.G.Ramirez-Molina, C.Shipley, T.J.Skone, P.A.Smithers, N.Somers, D.O.Walker, A.L.Watson, R.J.Weingarten, G.G.

(2011) Bioorg Med Chem Lett 21: 6188-6194

  • DOI: 10.1016/j.bmcl.2011.07.082
  • Primary Citation of Related Structures:  
    4YJU, 4YJO, 4YJP, 4YJQ, 4YJR, 4YJS, 4YJT, 3SRV

  • PubMed Abstract: 
  • The lead optimisation of the diaminopyrimidine carboxamide series of spleen tyrosine kinase inhibitors is described. The medicinal chemistry strategy was focused on optimising the human whole blood activity whilst achieving a sufficient margin over liabi ...

    The lead optimisation of the diaminopyrimidine carboxamide series of spleen tyrosine kinase inhibitors is described. The medicinal chemistry strategy was focused on optimising the human whole blood activity whilst achieving a sufficient margin over liability kinases and hERG activity. GSK143 is a potent and highly selective SYK inhibitor showing good efficacy in the rat Arthus model.


    Organizational Affiliation

    GlaxoSmithKline R&D, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, UK. john.2.liddle@gsk.com



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Tyrosine-protein kinase SYK A281Homo sapiensMutation(s): 0 
Gene Names: SYK
EC: 2.7.10.2
Find proteins for P43405 (Homo sapiens)
Explore P43405 
Go to UniProtKB:  P43405
NIH Common Fund Data Resources
PHAROS:  P43405
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
4DO
Query on 4DO

Download Ideal Coordinates CCD File 
A
N~2~-(1,1-dioxido-2,3-dihydro-1,2-benzothiazol-6-yl)-5-fluoro-N~4~-(1H-indazol-4-yl)-N~4~-methylpyrimidine-2,4-diamine
C19 H16 F N7 O2 S
AKKNJEBKJABIRC-UHFFFAOYSA-N
 Ligand Interaction
Modified Residues  1 Unique
IDChainsTypeFormula2D DiagramParent
PTR
Query on PTR
AL-PEPTIDE LINKINGC9 H12 N O6 PTYR
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
4DOIC50:  1.9900000095367432   nM  BindingDB
4DOIC50:  11.600000381469727   nM  BindingDB
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.67 Å
  • R-Value Free: 0.201 
  • R-Value Work: 0.167 
  • R-Value Observed: 0.168 
  • Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 39.299α = 90
b = 87.233β = 92.15
c = 40.077γ = 90
Software Package:
Software NamePurpose
MOSFLMdata reduction
SCALAdata scaling
BUSTERrefinement
PDB_EXTRACTdata extraction

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2015-09-30
    Type: Initial release